MRI diffusion-weighted imaging (MRI DWI) combined with PET/CT in the diagnosis and staging of stomach cancer (SC) was investigated. A retrospective analysis was performed on 160 patients with SC diagnosed by pathological biopsy in The Affiliated
Yantai Yuhuangding Hospital of Qingdao University . The values of MRI DWI; PET/CT and combin diagnosis in the diagnosis and staging of SC were compare according to the criteria of diagnosis of postoperative pathological or clinical comprehensive evaluation.
PET/CT in the diagnosis
The sensitivity, specificity and diagnostic coincidence rate of MRI DWI in the diagnosis of SC at stage I-II were 61.05, 64.62 and 62.50%; respectively, which were significantly lower than those of PET/CT (P<0.05). Sensitivity; specificity and diagnostic coincidence rate of MRI DWI in the diagnosis of SC at stage III-IV were lower than those of PET/CT (P<0.05). Sensitivity and diagnostic coincidence rate of MRI DWI combined with PET/CT in the diagnosis of SC at stage I-II were significantly higher than those of MRI DWI or PET/CT alone (P<0.05).
Specificity and diagnostic coincidence rate of MRI DWI combined with PET/CT in the diagnosis of SC at stage III-IV were significantly higher than those of MRI DWI or PET/CT alone (P<0.05). PET/CT is superior to MRI DWI in SC staging; whereas the diagnostic efficiency of combined scan is much higher than that of PET/CT or MRI DWI alone.
Diagnostic coincidence rate
In order to obtain more accurate preoperative staging and to avoid diagnostic exploratory laparotomy; the combination of MRI DWI and PET/CT techniques should be used in the comprehensive analysis of the disease to improve the accuracy of clinical diagnosis. Stomach cancer (SC); a malignant gastric cancer; originate from the most superficial mucosal epithelial cells of the gastric wall. According to the report released by the World Health Organization (WHO); the annual incidence of SC in the world is 14.23/100,000, and more than one million new SC are diagnose every year in the world.
The incidence rate of SC increases significantly with the increase of age; and the peak age range of the disease is 49-80 years, showing a younger trend. Purpose of SC staging is to evaluate the onset of the disease; to facilitate clinicians to summarize and communicate therapeutic effects; to conduct collaborative research on SC, and to develop treatment regimens.
Standard of clinical staging
Although pathological diagnosis is the golden standard of clinical staging of SC; some patients can not accept it psychologically and physiologically. Due to the development and innovation of medical diagnostic method; the imaging techniques used in clinical diagnosis are constantly upgrade; and the diagnostic coincidence rate is more and more close to pathological diagnosis.